Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) EPS (Basic) (2023 - 2026)

Contineum Therapeutics' EPS (Basic) history spans 4 years, with the latest figure at -$0.39 for Q1 2026.

  • Quarterly EPS (Basic) rose 37.1% to -$0.39 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$1.95 through Mar 2026, up 1.52% year-over-year, with the annual reading at -$2.17 for FY2025, 0.46% changed from the prior year.
  • EPS (Basic) came in at -$0.39 for Q1 2026, up from -$0.49 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $2.56 in Q2 2023 to a low of -$3.55 in Q1 2024.
  • The 4-year median for EPS (Basic) is -$0.53 (2023), against an average of -$0.79.
  • The largest YoY upside for EPS (Basic) was 85.13% in 2024 against a maximum downside of 115.23% in 2024.
  • Contineum Therapeutics' EPS (Basic) stood at -$0.53 in 2023, then decreased by 7.55% to -$0.57 in 2024, then grew by 14.04% to -$0.49 in 2025, then grew by 20.41% to -$0.39 in 2026.
  • Per Business Quant, the three most recent readings for CTNM's EPS (Basic) are -$0.39 (Q1 2026), -$0.49 (Q4 2025), and -$0.45 (Q3 2025).